• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Gabather

0.04 SEK

0.00 %

Less than 1K followers

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
+4.50 %
-33.01 %
+52.55 %
+39.33 %
-20.23 %
-94.91 %
-97.75 %
-99.01 %

Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Read more
Market cap
25.52M SEK
Turnover
91.2K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26/6
2026

General meeting '26

31/8
2026

Interim report Q2'26

27/11
2026

Interim report Q3'26

Third party research6/2/2026, 6:29 AM

Gabather: Phase II finally activated - VH Corp

* Phase II clinical trial activated * Cost control is still kept strict * We keep our fair value of SEK 0.06 per share Gabather's first report of 2026 came in close to our estimates, with an EBIT of KSEK -1 052 against our projected KSEK -1 136. The ...

Gabather
Press release6/2/2026, 6:00 AM

Västra Hamnen Market Focus: Gabather: Phase II finally activated

Gabather
Press release6/1/2026, 12:00 PM

Västra Hamnen Market Focus: Gabather presents Q1 2026

Gabather

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/29/2026, 3:45 PM

Gabather AB offentliggör årsredovisning för räkenskapsåret 2025

Gabather
Regulatory press release5/29/2026, 6:30 AM

Gabather publicerar delårsrapport 1 januari - 31 mars 2026

Gabather
Regulatory press release5/26/2026, 5:08 PM

Rättelse: KALLELSE TILL ÅRSSTÄMMA i Gabather AB (publ)

Gabather
Regulatory press release5/26/2026, 6:30 AM

KALLELSE TILL ÅRSSTÄMMA i Gabather AB (publ)

Gabather
Third party research5/8/2026, 6:24 AM

Gabather: Starting phase II clinical trial - VH Corp

* Approval to initiate the financed TOTEMS study * Patient enrolment imminent Gabather has announced the initiation of the TOTEMS study, a phase II clinical trial evaluating the drug candidate GT-002 in patients with schizophrenia spectrum disorders....

Gabather
Press release5/8/2026, 6:00 AM

Västra Hamnen Market Focus: Gabather: Starting phase II clinical trial

Gabather
Regulatory press release5/6/2026, 1:30 PM

Gabather tar klivet in i patientstudier - startar fas II med GT-002 i schizofreni

Gabather
Press release4/10/2026, 2:00 PM

Västra Hamnen Market Focus: Gabather comments on the new patent application

Gabather
Regulatory press release4/8/2026, 6:30 AM

Gabather AB: Gabather lämnar in patentansökan för ny icke-sederande sömnbehandling - expanderar till neural hälsa och hälsosamt åldrande

Gabather
Third party research3/19/2026, 11:32 AM

Gabather: Key shareholders show support - VH Corp

* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigger * We keep our fair value of SEK 0.06 per share Gabather has carried out a directed share issue of approximately MSEK 4.2 with participation from several...

Gabather
Press release3/19/2026, 9:00 AM

Västra Hamnen Market Focus: Gabather: Key shareholders show support

Gabather
Regulatory press release3/18/2026, 7:30 AM

Gabather AB: Gabather genomför en riktad emission av aktier om cirka 4,2 MSEK

Gabather
Third party research3/3/2026, 2:29 PM

Gabather: Any day now - VH Corp

* Exercise of warrants and a directed share issue extends runway * Phase II clinical trial expected to start very soon * After dilution, our fair value amounts to SEK 0.06 per share Gabather’s Q4 report showed lower-than-expected costs, primarily due...

Gabather
Press release3/3/2026, 2:00 PM

Västra Hamnen Market Focus: Gabather: Any day now

Gabather
Third party research3/3/2026, 12:50 PM

Gabather presents Q4 2025 - VH Corp

CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Västra Hamnen's analyst Jacob Murat.

Gabather
Press release3/3/2026, 12:30 PM

Västra Hamnen Market Focus: Gabather presents Q4 2025

Gabather
Regulatory press release2/27/2026, 7:30 AM

Gabather AB: Gabather publicerar bokslutskommuniké 1 Januari - 31 december 2025

Gabather